Lipid Metabolism

Lipid Metabolism, in cancer cell biology, is the coordinated reprogramming of de novo fatty acid and cholesterol biosynthesis, membrane lipid composition, and lipid storage that supports the substantial membrane biogenesis and signaling lipid requirements of rapidly proliferating cancer cells, encompassing both the specific biosynthetic enzyme machinery driving increased lipogenesis and the regulatory transcriptional programs controlling its activation. Complementing the extracellular lipid scavenging route described under nutrient uptake reprogramming, this topic addresses the internal biosynthetic machinery by which cancer cells generate lipids de novo from other metabolic precursors, along with the downstream consequences of altered lipid composition for membrane function and cell survival.

De Novo Lipogenesis Machinery

Cancer cells frequently upregulate the core enzymatic pathway for de novo fatty acid synthesis from citrate-derived acetyl-CoA, even in the presence of adequate extracellular lipid availability, reflecting an active biosynthetic program rather than a passive response to lipid scarcity:

ATP-citrate lyase (ACLY) converts mitochondrially derived citrate, exported to the cytosol as described under mitochondrial metabolism, into acetyl-CoA; acetyl-CoA carboxylase (ACC) subsequently carboxylates this into malonyl-CoA, the rate-limiting step of the pathway; and fatty acid synthase (FASN), a large multidomain enzyme catalyzing the full iterative chain-elongation cycle, produces the saturated fatty acid palmitate as the primary end product, which serves as the precursor for further elongation and desaturation into the full range of fatty acid species required for membrane phospholipid and signaling lipid synthesis.

SREBP Transcriptional Regulation

The lipogenic enzyme program is coordinately controlled by the sterol regulatory element-binding protein (SREBP) family of transcription factors, whose activity is directly coupled to oncogenic PI3K-AKT-mTOR signaling:

This coupling directly links the same growth-signaling pathways driving glucose and amino acid uptake reprogramming to coordinated activation of lipogenic gene expression, ensuring that lipid biosynthetic capacity scales in proportion to the same oncogenic signaling inputs governing overall cell growth, and providing a further specific example of the general principle that cancer metabolic reprogramming is directly, coherently orchestrated by oncogenic signaling rather than arising as an uncoordinated collection of independent alterations.

Saturation Balance and Stearoyl-CoA Desaturase

Beyond total lipid quantity, the balance between saturated and monounsaturated fatty acids in cancer cell membranes is actively regulated and functionally significant, controlled substantially through stearoyl-CoA desaturase 1 (SCD1), which introduces a double bond into saturated fatty acyl-CoA substrates to generate monounsaturated fatty acids:

Elevated SCD1 activity, frequently observed in cancer cells, increases the monounsaturated fatty acid content of membrane phospholipids, supporting the increased membrane fluidity and biophysical properties favorable to the rapid membrane trafficking and remodeling demands of actively proliferating and migrating cells, while also modulating susceptibility to lipid peroxidation-driven cell death pathways.

Diagram: De Novo Lipogenesis Pathway with Regulatory Control

Lipid Droplets and Protection from Lipotoxicity

Excess fatty acids, whether synthesized de novo or acquired through uptake, are frequently stored in cytoplasmic lipid droplets as neutral triglycerides and cholesterol esters rather than remaining as free fatty acids, a storage strategy that protects cancer cells from lipotoxicity, the cellular damage caused by excess free fatty acid accumulation, and provides a mobilizable lipid reserve; lipid droplet abundance is elevated in several aggressive cancer subtypes and has been specifically associated with a protective role against ferroptosis, an iron-dependent form of lipid peroxidation-driven cell death relevant to the drug-tolerant persister state vulnerability described under adaptive cancer cell states.

Therapeutic Targeting

Given the central, oncogene-coupled role of de novo lipogenesis, FASN and ACC inhibitors have been developed and evaluated clinically as cancer therapeutics, with FASN inhibition showing selective efficacy against tumors displaying strong dependence on de novo lipogenesis rather than extracellular lipid scavenging, while SCD1 inhibitors have been investigated both for direct anti-proliferative effects and for their capacity to sensitize cancer cells to ferroptosis-inducing agents by shifting membrane composition toward a more peroxidation-susceptible saturated lipid profile.

Experimental Assessment

Cancer lipid metabolism is assessed using stable isotope tracing with labeled acetate or glucose to quantify de novo lipogenic flux via mass spectrometry-based lipidomic analysis, quantification of lipid droplet abundance using fluorescent neutral lipid staining, genetic and pharmacological inhibition of ACLY, ACC, FASN, and SCD1 to establish functional lipogenic pathway dependence, and lipid peroxidation assays to characterize the relationship between membrane lipid saturation status and susceptibility to ferroptotic cell death.